Establishment and Characterization of a HER2-Positive Cell Line Derived From the Pleural Effusion of a Drug-Resistant Breast Cancer Patient.

Zhaoqing Li,Shuduo Xie,Wenying Zhuo,Jichun Zhou,Misha Mao,Qinchuan Wang,Dengdi Hu,Siwei Ju,Lini Chen,Cong Chen,Jingjing Yang,Yongxia Chen,Yulu Zhou,Ling Xu,Minjun Dong,Linbo Wang,Xun Zhang,Jun Shen

doi:10.3389/fcell.2021.680968

Abstract

Drug resistance is a daunting challenge in the treatment of breast cancer, making it an urgent problem to solve in studies. Cell lines are important tools in basic and preclinical studies; however, few breast cell lines from drug-resistant patients are available. Herein, we established a novel HER2-positive breast cancer cell line from the pleural effusion of a drug-resistant metastatic breast cancer patient. This cell line has potent proliferative capability and tumorigenicity in nude mice but weak invasive and colony-forming capability. The molecular subtype of the cell line and its sensitivity to chemotherapeutics and HER2-targeting agents are different from those of its origin, suggesting that the phenotype changes between the primary and metastatic forms of breast cancer.

Highlights

Breast cancer, the most common malignant tumor in women, causes half a million deaths worldwide per year (Harbeck and Gnant, 2017)
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for approximately 15–20% of all breast cancers, and its prognosis has been improved in the past two decades by new treatments such as trastuzumab, pertuzumab and lapatinib (Loibl and Gianni, 2017)
High rates of de novo resistance to trastuzumab are common in HER2-positive breast cancer in both metastatic and adjuvant settings (Martin-Castillo et al, 2013)

Summary

Introduction

The most common malignant tumor in women, causes half a million deaths worldwide per year (Harbeck and Gnant, 2017). Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for approximately 15–20% of all breast cancers, and its prognosis has been improved in the past two decades by new treatments such as trastuzumab, pertuzumab and lapatinib (Loibl and Gianni, 2017). High rates of de novo resistance to trastuzumab are common in HER2-positive breast cancer in both metastatic and adjuvant settings (Martin-Castillo et al, 2013). It is vital to explore and overcome the mechanism causing resistance.

Methods

Results

Conclusion